1.
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phas...
by Gaudet, Daniel, MD, PhD
The American journal of cardiology, 2014, Vol.114 (5), p.711-715
2.
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
by Akdim, Fatima, MD
The American journal of cardiology, 2010, Vol.105 (10), p.1413-1419
3.
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-con...
by Davidson, Michael H., MD
Clinical therapeutics, 2007, Vol.29 (7), p.1354-1367
4.
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
by Turner, Traci, MD
Clinical therapeutics, 2015, Vol.37 (12), p.2751-2769
5.
Safety and Tolerability of Dalcetrapib
by Stein, Evan A., MD, PhD
The American journal of cardiology, 2009, Vol.104 (1), p.82-91
6.
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging...
by Ballantyne, Christie M., MD
The American heart journal, 2012, Vol.163 (3), p.515-521.e3
7.
Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Si...
by Stein, Evan A., MD, PhD
The American journal of cardiology, 2008, Vol.101 (4), p.490-496
8.
Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease
by Stein, Evan A., MD, PhD
Mayo Clinic proceedings, 2009, Vol.84 (4), p.307-309
9.
Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia
by Stein, Evan A., MD, PhD
The American journal of cardiology, 2007, Vol.100 (9), p.1387-1396
10.
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable st...
by Stein, Evan A, Prof, Dr
The Lancet (British edition), 2012, Vol.380 (9836), p.29-36
11.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
by Fayad, Zahi A, Prof
The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559
12.
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
by Ballantyne, Christie M., MD
The American journal of cardiology, 2012, Vol.110 (7), p.984-992
13.
Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation
by Thongtang, Nuntakorn, MD
The American journal of cardiology, 2011, Vol.107 (3), p.387-392
14.
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer reg...
by Coleman, MP, Prof
The Lancet (British edition), 2011, Vol.377 (9760), p.127-138
15.
Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades
by Elis, Avishay, MD
The American journal of cardiology, 2011, Vol.108 (2), p.223-226
16.
Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin
by Bays, Harold E., MD
Mayo Clinic proceedings, 2010, Vol.85 (2), p.122-128
17.
Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins
by Asztalos, Bela F., PhD
The American journal of cardiology, 2007, Vol.99 (5), p.681-685
18.
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
by Chlebowski, Rowan T, Prof
The Lancet (British edition), 2009, Vol.374 (9697), p.1243-1251
19.
Effects of Maximal Doses of Atorvastatin Versus Rosuvastatin on Small Dense Low-Density Lipoprotein Cholesterol Levels
by Ai, Masumi, MD
The American journal of cardiology, 2008, Vol.101 (3), p.315-318
20.
Usefulness of Baseline Lipids and C-Reactive Protein in Women Receiving Menopausal Hormone Therapy as Predictors of Treatment-Related Coronary Events
by Bray, Paul F., MD
The American journal of cardiology, 2008, Vol.101 (11), p.1599-1605.e1
